Kelly Paul Edward 4
4 · RELMADA THERAPEUTICS, INC. · Filed Dec 19, 2023
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2023-12-15+65,672→ 65,672 totalExercise: $2.48From: 2024-03-15Exp: 2033-12-15→ Common Stock (65,672 underlying)
Footnotes (1)
- [F1]The option vests in 16 equal quarterly installments commencing on March 15, 2024.